Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thwarting Protein Production Slows Cancer Cells’ Malignant March

Published: Tuesday, July 23, 2013
Last Updated: Tuesday, July 23, 2013
Bookmark and Share
Protein production or translation is tightly coupled to a highly conserved stress response that cancer cells rely on for survival and proliferation.

In mouse models of cancer, targeted therapeutic inhibition of translation disrupts this survival response, dramatically slowing tumor growth and potentially rendering drug-resistant tumors vulnerable to other therapies.

From yeast to worms to humans, this stress response and its primary regulator, heat shock factor 1 (HSF1), help normal cells adapt to harsh environments, including the presence of heavy metals, high salt concentrations, low oxygen levels, and of course increased temperatures.

"In a perverted twist of fate, cancer cells take advantage of this incredibly ancient survival strategy—the heat shock response—to help them survive despite the best efforts of our own natural defenses, and sophisticated therapeutics, to kill them,” says Whitehead Member Susan Lindquist. “And trumping all that, we find it not only helps them survive, it helps them thrive!"

Across tumor and cancer types, cancer cells rely on the heat shock response and HSF1 to support the production of vast quantities of proteins and the high-energy demands needed to propel malignancy. Accordingly, researchers have envisioned HSF1 as a potential therapeutic target, but such transcriptional regulators have been notoriously difficult to target. However, by determining that protein translation is intimately connected to HSF1 activity, Whitehead scientists may have identified an approach to controlling cancer cells’ overactive heat shock response. Their work is described in this week’s issue of the journal Science.

“The genetic screens that we conducted in collaboration with the Broad Institute and the drug screens that were conducted by Sandro Santagata (Lindquist lab postdoctoral researcher) all pointed to this connection—that the process of protein production signals to HSF1,” says Marc Mendillo, a postdoctoral researcher in Lindquist’s lab and a coauthor of the Science paper with Santagata. “And this link may explain the HSF1 activation we have observed across an extraordinarily broad range of human cancers.”

Santagata’s screens identified one compound that was particularly effective at disrupting translation and HSF1 activity. Collaborators at Boston University synthesized an analog of this compound, called Rohinitib (RHT), that is even more efficacious. Normal cells are relatively resistant to RHT and seem to be little affected by it. However, cells from a wide spectrum of cancers are sensitive to it—RHT added to cancer cells in vitro normalizes their metabolism, including the increased glucose uptake characteristic of such cells, and even kills them. Blood cancer lines are highly sensitive to RHT and show the most dramatic effects. In mice implanted with human myeloid leukemia tumors, RHT greatly inhibited the tumors’ growth and suppressed glucose uptake, similar to the effects seen in vitro.

“I think we’ve found a very simple but elegant biological principle here, which makes sense,” says Santagata. “Systems in the cell that need to work together—such as protein translation and the heat shock response—actually are linked together. We found that link using small molecules, which means that we now have the tools in hand to suppress what cancer has coopted. We can use those chemicals to thwart the cancer cells’ ability to harness the properties of HSF1.

Such chemicals may be enough to knock cancer cells off balance, but the final coup de grace may need to come from other therapeutics.

“You probably want to have these kinds of effects in the context of other therapeutic interventions,” says Luke Whitesell, an oncologist and senior research scientist in the Lindquist lab. “If you were to compromise the altered physiology of tumors with something like RHT, the cancer cells are going to be less able to tolerate other therapeutic insults, and that probably would give you more effective therapies. But we don’t know what the best combinations are going to be yet.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tracking Changes in DNA Methylation In Real Time At Single-Cell Resolution
Whitehead Institute researchers have developed a methodology to monitor changes in DNA methylation over time in individual cells.
Friday, September 25, 2015
Super-Enhancers Seen as ‘Rosetta Stone’ for Dialog Between Genes and Disease
Regulatorsthat control cell identity found to be enriched in mutated regions of genome.
Monday, October 21, 2013
Scientists Identify Gene that Controls Aggressiveness in Breast Cancer Cells
Researchers have identified a transcription factor, known as ZEB1, that is capable of converting non-aggressive basal-type cancer cells into highly malignant, tumor-forming cancer stem cells (CSCs).
Monday, July 08, 2013
Putting microRNAs on the Stem Cell Map
Whitehead researchers have now discovered how microRNAs fit into the map of embryonic stem cell circuitry.
Friday, August 08, 2008
Scientists Identify Gene that Regulates Polarity in Regenerating Flatworms
Whitehead scientists have discovered that the gene Smed-beta-catenin-1 is required for proper decisions about head-versus-tail polarity in regenerating flatworms.
Monday, December 10, 2007
Scientific News
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!